LekoskopLekoskop
EN All changes
Medicine recalls and shortages › Drug Safety Update › 10 Apr 2025
Drug Safety Update

Fezolinetant▼(Veoza)

Published on 10 Apr 2025 · source: MHRA — Medicines and Healthcare products Regulatory Agency
Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during trea…
Drug Safety Update on GOV.UK ↗ All events: Fezolinetant▼(Veoza)

What this means

Drug Safety Update is the MHRA bulletin for healthcare professionals: new safety information, restrictions of use and recommendations for monitoring.

Summary

Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients taking fezolinetant. Fezolinetant should be avoided in patients with known liver disease or at a higher risk of liver disease.

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.